Salix Pharmaceuticals Ltd (SLXP) Tops Q2 EPS by 24c

Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $0.79, $0.24 better than the analyst estimate of $0.55. Revenue for the quarter came in at $181 million versus the consensus estimate of $180.79 million.

For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Piper Sandler on Virtu Financial (VIRT): 'The most overlooked name in our coverage'
• First Watch (FWRG) PT Lowered to $15 at DA Davidson, Buy Rating Maintained